|
Luspatercept
Hi everyone! You may already know this, but the drug Luspatercept has been FDA approved for treatment in beta thalassemia. Nope, not for low/intermediate risk MDS yet, but it’s approval for the one disease is very encouraging, I think. It has been shown to decrease transfusion dependence significantly in MDS. I think the target approval for MDS is April, 2020. So not that much longer to wait! It primarily was studied, I believe, for those MDS patients who have ring sideroblasts. I do not have those, so wonder if it will be strictly enforced. I asked my physician about that, and she thought there might be a way. We shall see! At any rate, we have some good news for a change.
__________________
Margaret, age 68, dx MDS 5 q- 5/09- now RCMD; also MGUS. TP53 and TET2 mutations
Last edited by Neil Cuadra : Wed Dec 4, 2019 at 07:40 PM.
Reason: removed extraneous linebreak
|